secwatch.observer — SEC 8-K summary
======================================

Issuer:     MiNK Therapeutics, Inc. (INKT)
CIK:        0001840229
Form:       8-K
Filed at:   2025-12-08T23:59:59+00:00
Accession:  0001193125-25-311229
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MiNK Therapeutics Q3 net loss $2.9M; durable remissions with agenT-797, cash runway through 2026
--------------------------------------------------------------------------------

- Net loss $2.9M ($0.65/share) in Q3 2025 vs $1.8M ($0.46) in Q3 2024.
- Cash $14.3M at quarter-end; raised $1.2M post-quarter; runway extended through 2026.
- Clinical data: durable complete remissions >2 years in refractory cancers; no Grade 3+ CRS/neurotoxicity.
- Launching Phase 1 GvHD study with UW-Madison, funded by NIH and philanthropy.
- Appointed Dr. Terese Hammond as Head of Inflammatory and Pulmonary Diseases, Dr. Holcomb to Board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840229/000119312525311229/0001193125-25-311229-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840229/000119312525311229/inkt-20251114.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-311229

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer